CN110180096A - A kind of method of ultrashort wave adjuvant treatment children's herpangina - Google Patents
A kind of method of ultrashort wave adjuvant treatment children's herpangina Download PDFInfo
- Publication number
- CN110180096A CN110180096A CN201910445989.XA CN201910445989A CN110180096A CN 110180096 A CN110180096 A CN 110180096A CN 201910445989 A CN201910445989 A CN 201910445989A CN 110180096 A CN110180096 A CN 110180096A
- Authority
- CN
- China
- Prior art keywords
- ultrashort wave
- herpangina
- treatment
- therapy
- adjuvant treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N7/00—Ultrasound therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2210/00—Anatomical parts of the body
- A61M2210/06—Head
- A61M2210/0625—Mouth
- A61M2210/065—Throat; Pharynx
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N7/00—Ultrasound therapy
- A61N2007/0004—Applications of ultrasound therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N7/00—Ultrasound therapy
- A61N2007/0043—Ultrasound therapy intra-cavitary
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Anesthesiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Otolaryngology (AREA)
- Oncology (AREA)
- Radiology & Medical Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention discloses a kind of methods of ultrashort wave adjuvant treatment children's herpangina, comprising the following steps: S1 treatment object, S2 exclude screening, S3 drug therapy, S4 ultrashort wave therapy and S5 and observe and record the state of an illness.Increase lesion local drug concentration by the high frequency magnetic field of generation, enhances curative effect of medication.Vasopermeability can be enhanced simultaneously, promote local blood circulation, accelerate the dissipation of oedema and the excretion and elimination of metabolite, inflammatory products and bacteriotoxin, low dose of ultrashort wave can enhance monokaryon-mononuclear phagocyte system function, phagocyte quantity increases, phagocytic function enhancing, internal globulin, antibody, complement, agglutinin increase, alkaline phosphatase activities increase in peripheral blood leucocytes, LeIF potency increases, be conducive to the control and dissipation of inflammation, ultrashort wave can effectively inhibit the conduction of the patient feels nerve, thus reduction of patient feeling of pain.
Description
Technical field
The present invention relates to ultrasonic therapy children's herpangina technical field, specially a kind of ultrashort wave adjuvant treatment
The method of children's herpangina.
Background technique
Herpangina is a kind of common Pediatric Acute infectious disease, there is disease incidence and infectious rate with higher, main
To be caused by Coxsackie virus infection, clinical manifestation is pharyngeal pain, salivation, nausea, anorexia etc..Infant is because of pharyngeal blister when morbidity
Rash and pain often can it is irritated, cry and scream, eating difficulties affect infant health, also bring great pain to household.Herpetic pharynx
Gorge inflammation is self-limited disease (1-2 weeks), and active treatment can shorten the course of disease, prevent related complication.Herpangina is paediatrics
More typical communicable disease, natural history is mostly at 1 week or so, and herpangina is using typical isthmus faucium portion as principal pathogenetic portion
Position, it is the main positions of the infection of the upper respiratory tract caused by virus that peripheral lymphoid circulation is abundant.If nervous system is involved in infection, can be simultaneously
It sends out encephalitis and neurogenic pulmonary edema serious, even results in nervous system dysfunction and multiple organ injury.It there is no spy at present
Treatment method is imitated, mainly based on supportive treatment of suiting the medicine to the illness.Ultrashort wave is treated as a kind of physiotherapy factor, extensively in recent years
Applied to the treatment of the diseases such as infantile pneumonia, rhinitis, parotitis, still, blister seldom but is applied to and without by ultrashort wave
In the treatment of rash angina, for this purpose, providing a kind of method for being used to assist in the treatment of herpangina for ultrashort wave.
Summary of the invention
The purpose of the present invention is to provide a kind of methods of ultrashort wave adjuvant treatment children's herpangina, on solving
State the problem of proposing in background technique.
To achieve the above object, the invention provides the following technical scheme: a kind of ultrashort wave assists in the treatment of the herpetic pharynx of children
The method of gorge inflammation, it is characterised in that: the following steps are included:
S1: treatment object: 1. meet the diagnostic criteria [2] of herpangina in " Zhu Futang practical paidonosology " the 8th edition；
2. the age 1-7 years old；
S2: it excludes screening: in the treatment object of step S1, excluding the patient for having following any situation, 1. whole body
Chronic disease, tumour and there is metallic foreign body etc. to have ultrashort wave therapy taboo person in vivo；2. infant C-RP is higher than 80mg/L or more
Person；3. switching to hand-foot-and-mouth disease person in treatment；4. complication or adverse reactions people are mismatched or occur in midway treatment；
S3: drug therapy: routine medication is used；
S4: ultrashort wave therapy: after the drug therapy of step S3, patient's lesions position is controlled by ultrasonic instrument
It treats, ultrasonic frequency is 30~300MHz, and wavelength is the electric current of 1~10m, one day 1~3 time, every time 6~8min, the course for the treatment of 3~5
It；
S5: it observes and records the state of an illness: 1. recording patient temperature and situation of bringing down a fever；2. observing mucous membrane of mouth and pharyngeal bleb subsiding
Situation, and record regression time；3. observing adverse reaction.
Preferably, the conventional medicine is interferon nebulae inhalation.
Preferably, the ultrasonic instrument is low-power, and output power is 50~80W.
Preferably, the electrode to the distance between skin be 20~24mm.
Preferably, the frequency of the ultrasonic wave is 40.68MHz, wavelength 7.37m.
Preferably, the dosage of the ultrasonic therapy is low dose without heat.
Compared with prior art, the beneficial effects of the present invention are:
1, lesion local drug concentration is increased by the high frequency magnetic field of generation, enhances curative effect of medication.Blood vessel can be enhanced simultaneously
Permeability, promote local blood circulation, accelerate the dissipation and metabolite of oedema, the excretion of inflammatory products and bacteriotoxin and
It eliminates；
2, low dose of ultrashort wave can enhance monokaryon-mononuclear phagocyte system function, and phagocyte quantity increases, phagocytic function
Enhancing, internal globulin, antibody, complement, agglutinin increase, and alkaline phosphatase activities increase in peripheral blood leucocytes, white thin
Born of the same parents' interferon potency increases, and is conducive to the control and dissipation of inflammation；
3, ultrashort wave can effectively inhibit the conduction of the patient feels nerve, thus reduction of patient feeling of pain.
The rehabilitation course for thus accelerating patient alleviates the painful time of patient, and infant fitness is high, without bad anti-
It answers, is worth clinically wideling popularize.
Specific embodiment
Below in conjunction with the embodiment of the present invention, technical scheme in the embodiment of the invention is clearly and completely described,
Obviously, described embodiments are only a part of the embodiments of the present invention, instead of all the embodiments.Based in the present invention
Embodiment, every other embodiment obtained by those of ordinary skill in the art without making creative efforts, all
Belong to the scope of protection of the invention.
Embodiment 1
A kind of method of ultrashort wave adjuvant treatment children's herpangina, comprising the following steps:
S1: treatment object: 1. meet the diagnostic criteria [2] of herpangina in " Zhu Futang practical paidonosology " the 8th edition；
2. the age 1-7 years old；
S2: it excludes screening: in the treatment object of step S1, excluding the patient for having following any situation, 1. whole body
Chronic disease, tumour and there is metallic foreign body etc. to have ultrashort wave therapy taboo person in vivo；2. infant C-RP is higher than 80mg/L or more
Person；3. switching to hand-foot-and-mouth disease person in treatment；4. complication or adverse reactions people are mismatched or occur in midway treatment；
S3: drug therapy: using routine medication, and conventional medicine is interferon nebulae inhalation；
S4: ultrashort wave therapy: after the drug therapy of step S3, patient's lesions position is controlled by ultrasonic instrument
It treats, ultrasonic instrument is low-power, it is relatively common, such as the production of Shanghai Shanghai Medical Instrument High Technology Company, there are multiple systems
Column may be implemented, output power 50W, ultrasonic frequency 30MHz, and the distance between electrode to skin is 20mm, and wavelength is
The electric current of 1m, once a day, each 6min, the course for the treatment of 3 days, the dosage of ultrasonic therapy was low dose without heat；
S5: it observes and records the state of an illness: 1. recording patient temperature and situation of bringing down a fever；2. observing mucous membrane of mouth and pharyngeal bleb subsiding
Situation, and record regression time；3. observing adverse reaction.
Embodiment 2
A kind of method of ultrashort wave adjuvant treatment children's herpangina: the following steps are included:
S1: treatment object: 1. meet the diagnostic criteria [2] of herpangina in " Zhu Futang practical paidonosology " the 8th edition；
2. the age 1-7 years old；
S2: it excludes screening: in the treatment object of step S1, excluding the patient for having following any situation, 1. whole body
Chronic disease, tumour and there is metallic foreign body etc. to have ultrashort wave therapy taboo person in vivo；2. infant C-RP is higher than 80mg/L or more
Person；3. switching to hand-foot-and-mouth disease person in treatment；4. complication or adverse reactions people are mismatched or occur in midway treatment；
S3: drug therapy: using routine medication, and conventional medicine is interferon nebulae inhalation；
S4: ultrashort wave therapy: after the drug therapy of step S3, patient's lesions position is controlled by ultrasonic instrument
It treats, ultrasonic instrument is low-power, it is relatively common, such as the production of Shanghai Shanghai Medical Instrument High Technology Company, there are multiple systems
Column may be implemented, output power 60W, and the distance between electrode to skin is 22mm, and the frequency of ultrasonic wave is 40.68MHz,
Wavelength 7.37m, two times a day, each 7min, the course for the treatment of 4 days, the dosage of ultrasonic therapy was low dose without heat；
S5: it observes and records the state of an illness: 1. recording patient temperature and situation of bringing down a fever；2. observing mucous membrane of mouth and pharyngeal bleb subsiding
Situation, and record regression time；3. observing adverse reaction.
Embodiment 3
A kind of method of ultrashort wave adjuvant treatment children's herpangina, comprising the following steps:
S1: treatment object: 1. meet the diagnostic criteria [2] of herpangina in " Zhu Futang practical paidonosology " the 8th edition；
2. the age 1-7 years old；
S2: it excludes screening: in the treatment object of step S1, excluding the patient for having following any situation, 1. whole body
Chronic disease, tumour and there is metallic foreign body etc. to have ultrashort wave therapy taboo person in vivo；2. infant C-RP is higher than 80mg/L or more
Person；3. switching to hand-foot-and-mouth disease person in treatment；4. complication or adverse reactions people are mismatched or occur in midway treatment；
S3: drug therapy: using routine medication, and conventional medicine is interferon nebulae inhalation；
S4: ultrashort wave therapy: after the drug therapy of step S3, patient's lesions position is controlled by ultrasonic instrument
It treats, ultrasonic instrument is low-power, it is relatively common, such as the production of Shanghai Shanghai Medical Instrument High Technology Company, there are multiple systems
Column may be implemented, output power 80W, ultrasonic frequency 300MHz, and the distance between electrode to skin is 24mm, and wavelength is
The electric current of 10m, three times a day, each 8min, the course for the treatment of 5 days, the dosage of ultrasonic therapy was low dose without heat；
S5: it observes and records the state of an illness: 1. recording patient temperature and situation of bringing down a fever, 2. observes mucous membrane of mouth and pharyngeal bleb recession
Situation, and record regression time, 3. observe adverse reaction.
It is compared by three groups of embodiments, 2 effect of embodiment is more preferable, becomes apparent from, that is to say, that power 60W, electrode to skin
The distance between be 22mm, the frequency of ultrasonic wave is 40.68MHz, wavelength 7.37m, and two times a day, each 7min is imitated for the course for the treatment of 4 days
Fruit is relatively good, also reflects, and has had reached within 4 days therapeutic effect, and the 5th day unobvious on the basis of taking a turn for the better.
Increase lesion local drug concentration by the high frequency magnetic field of generation, enhances curative effect of medication.It is logical that blood vessel can be enhanced simultaneously
Permeability promotes local blood circulation, accelerates the dissipation and metabolite of oedema, the excretion of inflammatory products and bacteriotoxin and disappear
It removes, low dose of ultrashort wave can enhance monokaryon-mononuclear phagocyte system function, and phagocyte quantity increases, and phagocytic function enhances this
It is a China Rehabilitation theory and practice in June, 2018 volume 24 the 6th it is interim " ultrashort wave promotes macrophage phenotype conversion simultaneously
Inhibit the effect of inflammatory reaction after Spinal Cord Injury in Rats " in just illustrate, during ultrashort wave therapy, phagocyte is from M1 to M2
Type transformation, it is well known that the killing ability of M2 is stronger, and effect is more preferable, so as to shorten the anginal course of disease；
Internal globulin, antibody, complement, agglutinin increase, and alkaline phosphatase activities increase in peripheral blood leucocytes, white
Cell Interferon potency increases, and is conducive to the control and dissipation of inflammation；
Ultrashort wave can effectively inhibit the conduction of the patient feels nerve, thus reduction of patient feeling of pain.[Wen Xinyi, Cai Ai
Precious ultrashort wave and pulsating field treat 423 observation of curative effect [J] China Rehabilitations of mumps, 1993,8 (2): 136-
137.]
Experimental comparison
1, personnel choose: choosing the herpetic pharynx that peace one attached institute, medical university, 2 months 2018~2 months 2019 Pediatric Clinics are seen and treated patients
Gorge inflammation infant 112.According to medical sequence, it is randomly divided into control group 56 and experimental group 56.Control group male 26, female 30, put down
The equal age (3.8 ± 0.9 one full year of life)；Experimental group male 29, female 27, average age (3.9+1.0 one full year of life)；Two groups of infants are at age, property
Not aspect comparing difference is not statistically significant (P > 0.05), is comparable.
2, it is included in standard: 1. meeting the diagnostic criteria [2] of herpangina in " Zhu Futang practical paidonosology " the 8th edition；
2. the age 1-7 years old；3. the course of disease was less than 2 days；4. not receiving treatment before medical；5. parents of hospitalized children knows and is ready to cooperate this research,
Sign informed consent form；
1. exclusion criteria whole body chronic disease, tumour and has metallic foreign body etc. to have ultrashort wave therapy taboo person in vivo；②
Infant C-RP is higher than 80mg/L or more person；3. switching to hand-foot-and-mouth disease person in treatment；4. complication is mismatched or is occurred in midway treatment
And adverse reactions people；
3, condition: control group is using conventional drug therapy, that is, interferon is atomized and relieving cough and reducing sputum drug therapy is same
When use, treat 5 days, experimental group increases ultrashort wave therapy, power 60W, electrode to skin on the basis of routine medication
The distance between be 22mm, the frequency of ultrasonic wave is 40.68MHz, wavelength 7.37m, and two times a day, each 8min the course for the treatment of 5 days, is treated
Criterion is imitated according to the standard of curative effect evaluation [2] in " practical paidonosology ".It is divided into effective, effective and invalid: 1. effective: 3 days
Interior temperature recovery is normal, and bleb disappears, and feed is good, and ulcer surface starts to heal；2. effectively: body temperature peak descending, fever in 3 days
Interval time increases, and the symptoms were significantly improved for pharyngalgia, and feed improves, and bleb significantly reduces, and ulcer surface still has redness, and faces in 5 days
Bed symptom, sign disappear；3. invalid: the state of an illness does not disappear without symptom, sign in improvement, or even exacerbation or 5 days in 3 days.Always
Efficient=(effective+effectively) and/total number of cases × 100%, obvious effective rate=effective/total number of cases × 100%.Statistics is as follows:
1 patients ' recovery situation of table
2 two groups of infant curative effects of table compare
3 two groups of infant fever times of table, bleb regression time compare
Experimental group total effective rate (94.6%) is higher than control group (87.5%) after treatment, and effective number of cases is apparently higher than control
Group, difference are statistically significant (p < 0.05)；The fever time (2.2 ± 0.58) of experimental group be shorter than control group (2.72 ±
0.59), difference is statistically significant (p < 0.05)；Experimental group infant bleb, which is moved back, disappears the time (2.62 ± 0.56) also below control
(3.30 ± 0.71) of group, it is statistically significant (p < 0.05) compared to difference, do not occur in two groups of therapeutic process bad anti-
It answers.It illustrates to be remarkably improved curative effect better than simple drug therapy using ultrashort wave adjuvant treatment children's herpangina,
Accelerate fever time and bleb regression time, is worth clinical expansion.
Note: it may be noted that because children's vessel wall elasticity is poor, nervus vasculairs function is more adult to be easier to disorder, treatment time
If too long, may locally there be bleeding, therefore the ultrashort wave therapy time also foreshortens to 8 minutes/time in this research.In addition, small
Youngster's epiphysis, eye are sensitive to ultrashort wave, should not use large dosage of [physiatrics], ultrashort therapeutic dose is in this research
It is low dose of.
It although an embodiment of the present invention has been shown and described, for the ordinary skill in the art, can be with
A variety of variations, modification, replacement can be carried out to these embodiments without departing from the principles and spirit of the present invention by understanding
And modification, the scope of the present invention is defined by the appended.
Claims (6)
1. a kind of method of ultrashort wave adjuvant treatment children's herpangina, it is characterised in that: the following steps are included:
S1: treatment object: 1. meet the diagnostic criteria [2] of herpangina in " Zhu Futang practical paidonosology " the 8th edition；2. year
Age 1-7 years old；
S2: it excludes screening: in the treatment object of step S1, excluding the patient for having following any situation, 1. whole body is chronic
Disease, tumour and there is metallic foreign body etc. to have ultrashort wave therapy taboo person in vivo；2. infant C-RP is higher than 80mg/L or more person；③
Switch to hand-foot-and-mouth disease person in treatment；4. complication or adverse reactions people are mismatched or occur in midway treatment；
S3: drug therapy: routine medication is used；
S4: ultrashort wave therapy: after the drug therapy of step S3, treating patient's lesions position by ultrasonic instrument,
Ultrasonic frequency is 30~300MHz, and wavelength is the electric current of 1~10m, one day 1~3 time, every time 6~8min, the course for the treatment of 3~5 days；
S5: it observes and records the state of an illness: 1. recording patient temperature and situation of bringing down a fever；2. observing mucous membrane of mouth and pharyngeal bleb recession feelings
Condition, and record regression time；3. observing adverse reaction.
2. a kind of method of ultrashort wave adjuvant treatment children's herpangina according to claim 1, it is characterised in that:
The conventional medicine is interferon nebulae inhalation.
3. a kind of method of ultrashort wave adjuvant treatment children's herpangina according to claim 1, it is characterised in that:
The ultrasonic instrument is low-power, and output power is 50~80W.
4. a kind of method of ultrashort wave adjuvant treatment children's herpangina according to claim 3, it is characterised in that:
The electrode to the distance between skin be 20~24mm.
5. a kind of method of ultrashort wave adjuvant treatment children's herpangina according to claim 3, it is characterised in that:
The frequency of the ultrasonic wave is 40.68MHz, wavelength 7.37m.
6. a kind of method of ultrashort wave adjuvant treatment children's herpangina according to claim 1, it is characterised in that:
The dosage of the ultrasonic therapy is low dose without heat.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910445989.XA CN110180096A (en) | 2019-05-27 | 2019-05-27 | A kind of method of ultrashort wave adjuvant treatment children's herpangina |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910445989.XA CN110180096A (en) | 2019-05-27 | 2019-05-27 | A kind of method of ultrashort wave adjuvant treatment children's herpangina |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110180096A true CN110180096A (en) | 2019-08-30 |
Family
ID=67717960
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910445989.XA Pending CN110180096A (en) | 2019-05-27 | 2019-05-27 | A kind of method of ultrashort wave adjuvant treatment children's herpangina |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110180096A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2198704C1 (en) * | 2001-10-16 | 2003-02-20 | Научно-клинический центр оториноларингологии | Method for treating the cases of pharyngitis |
| CN1795947A (en) * | 2004-12-24 | 2006-07-05 | 重庆融海超声医学工程研究中心有限公司 | Ultrasonic therapy gun |
| CN101085397A (en) * | 2006-06-07 | 2007-12-12 | 重庆海扶(Hifu)技术有限公司 | Optical sight glass orthoptic ultrasonic therapy system |
| CN104324450A (en) * | 2014-04-11 | 2015-02-04 | 秦皇岛嘎哈医疗电子仪器有限公司 | Ultra-optical-frequency pulverization treatment instrument |
-
2019
- 2019-05-27 CN CN201910445989.XA patent/CN110180096A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2198704C1 (en) * | 2001-10-16 | 2003-02-20 | Научно-клинический центр оториноларингологии | Method for treating the cases of pharyngitis |
| CN1795947A (en) * | 2004-12-24 | 2006-07-05 | 重庆融海超声医学工程研究中心有限公司 | Ultrasonic therapy gun |
| CN101085397A (en) * | 2006-06-07 | 2007-12-12 | 重庆海扶(Hifu)技术有限公司 | Optical sight glass orthoptic ultrasonic therapy system |
| CN104324450A (en) * | 2014-04-11 | 2015-02-04 | 秦皇岛嘎哈医疗电子仪器有限公司 | Ultra-optical-frequency pulverization treatment instrument |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103432265B (en) | A kind of Chinese medicinal composition preparation treating fever of children and preparation method thereof | |
| CN107669881A (en) | A kind of Chinese medicine for treating acute bronchitis in children | |
| CN110180096A (en) | A kind of method of ultrashort wave adjuvant treatment children's herpangina | |
| CN115887514B (en) | Pain-relieving ointment and preparation method thereof | |
| CN103830482B (en) | A kind of Chinese medicine preparation and preparation method for the treatment of apoplexy | |
| CN103417614A (en) | Traditional Chinese medicine for treating hemorrhoid | |
| CN103845646B (en) | A kind of Chinese medicine for the treatment of epilepsy | |
| CN105147796B (en) | A kind of Chinese medicine for treating type insomnia of having a guilty consicence | |
| CN104000936A (en) | Traditional Chinese medicament for treating epilepsy | |
| CN104623382B (en) | A kind of Chinese medicine for treating type of phlegm-heat attacking internally insomnia | |
| CN102188625B (en) | Traditional Chinese medicine capable of treating epilepsy after cerebral infarction | |
| CN102813888B (en) | Chinese herbal composition for treating epilepsy | |
| CN104784495A (en) | Traditional Chinese medicine preparation for treating infantile convulsion and preparation method | |
| CN103550327A (en) | Preparation method of medicament for healing of wound | |
| CN104257954A (en) | Traditional Chinese medicine preparation for treating epilepsy | |
| CN105232991B (en) | A kind of pharmaceutical composition for treating mucosal lesion | |
| CN102430069A (en) | Traditional Chinese medicine for treating delayed epilepsia after cerebral hemorrhage | |
| WO2022037577A1 (en) | Contact and introduction device, application thereof, and corresponding contact and introduction method | |
| CN101890076B (en) | Traditional Chinese medicine oral preparation for treating sores and ulcers | |
| CN105998720A (en) | Chinese medicinal preparation for treatment of children bronchial pneumonia and preparation method | |
| CN109745342A (en) | It is a kind of for treat the Chinese medicine composition of idiopathic epilepsy with and preparation method thereof and application method | |
| CN105456329A (en) | Rheumatism pain alleviating medicinal liquor | |
| Lu et al. | Chinese medicinal herb therapy for the rehabilitation of peripheral facial palsy | |
| Kunfeng et al. | Comparison of Preoperative Sedation Effect of Dexmedetomidine Nasal Spray at Different Doses in Children with Cleft Palate | |
| CN104524297A (en) | Traditional Chinese medicine for treating kidney-yang insufficiency type allergic rhinitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20190830 |
|
| WD01 | Invention patent application deemed withdrawn after publication |